Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Holoprosencephaly
Holoprosencephaly
Holoprosencephaly
Synonyms: HPE
Synonyms: HPE
Synonyms: HPE
Drug discovery
171
papers
On emerging therapies
Rare developmental defect during embryogenesis
Holoprosencephaly
Overview
Holoprosencephaly (HPE) is a congenital brain malformation caused by incomplete midline cleavage of the prosencephalon (forebrain) during early embryogenesis. It ranges in severity from mild (lobar) to severe (alobar) forms, with associated craniofacial anomalies, developmental delays, seizures, endocrine dysfunction, and motor impairments. Etiology includes chromosomal abnormalities (e.g., Trisomy 13), pathogenic variants in SHH, ZIC2, or SIX3 genes, and environmental factors like maternal diabetes. Diagnosis involves prenatal ultrasound/MRI and genetic testing. Management is symptomatic and multidisciplinary, focusing on optimizing neurologic, respiratory, and endocrine function [1][4][15].
Burden
Mortality: 97% prenatal demise; severe cases (alobar) often fatal within 6 months [1][13].
Morbidity: Universal developmental delay, with 40-50% experiencing seizures and 80% requiring lifelong assistance for feeding/mobility [1][8][15].
Healthcare utilization: High demand for multidisciplinary care, frequent hospitalizations, and specialized equipment [1][3][13].
Therapies
Medical: Antiseizure medications, hormone replacement (e.g., DDAVP for diabetes insipidus), and treatment for reflux/respiratory issues [1][8][13].
Surgical: Shunts for hydrocephalus, cleft repair, and gastrostomy tubes (required in ~75% of cases) [1][6][13].
Supportive: Physical, occupational, and speech therapies; mobility/communication aids [1][3][6].
Categories: rare developmental anomalies during embryogenesis, rare endocrine diseases, rare genetic diseases, rare neurological diseases
Research Papers
171 drug discovery papers about Holoprosencephaly. Recent publications:
171 drug discovery papers about Holoprosencephaly. Recent publications:
categories:
Small molecules
small molecules
2026-06-30 | Chorea misinterpreted as agitation in a 15-month-old girl with semilobar holoprosencephaly: a case report
We report the case of a 15-month-old girl with semilobar holoprosencephaly, microcephaly, central diabetes insipidus, failure to thrive, and severe global developmental delay who was admitted to the pediatric intensive care unit for aspiration pneumonia requiring mechanical ventilation.Caregivers reported long-standing severe irritability and poor sleep, for which she had been taking melatonin and diazepam before admission.During ventilator weaning, persistent irritability, irregular breathing, and excessive nonrhythmic movements were repeatedly interpreted as agitation, leading to increased analgesic and sedative requirements, including sufentanil and midazolam infusions and intermittent rescue chloral hydrate, and contributing to a prolonged ventilatory course.The movements were involuntary and irregular, worsened during wakefulness, and resolved during sleep.Electroencephalography revealed no electrographic seizures or epileptiform discharges and showed a poorly organized background consistent with the underlying structural brain disease.After chorea was suspected, pediatric neurology was consulted.Additional caregiver history suggested that similar involuntary movements had occurred before admission and may have contributed to her long-standing irritability and poor sleep.Treatment with clonazepam and dopamine receptor antagonists, including haloperidol and risperidone, reduced the movements and improved clinical stability, enabling transfer to the ward and subsequent discharge.This case illustrates that chorea may be mistaken for agitation in neurologically impaired infants or toddlers and that careful observation of the movement pattern, including suppression during sleep, may facilitate recognition and limit unnecessary escalation of sedation.
2026-06-17 | Congenital and Developmental Disorders: A Field-Geometry Account
Development is not the execution of a genetic program. It is a field-geometry process — one in which the embryo functions as a self-organizing tensor field that reads positional information, resolves chemical and mechanical gradients, and locks into stable configurations we recognize as organs, limbs, bones, and neural circuits. In this framework, the genome does not specify anatomy any more than a tuning dial specifies the music coming out of a radio. Genes tune the field. The field makes the shape. Congenital and developmental disorders, viewed through this lens, are not random errors in a recipe. They are geometry-drift events: instances where the morphogenetic field resolved to a wrong attractor, failed to complete a topological transition, or operated on corrupted positional-information gradients. This manuscript develops that argument across four interlocking pillars. The first establishes the conceptual foundation: morphogenesis is a field-geometry phenomenon, governed by reaction-diffusion dynamics, gradient superposition, mechanical stress fields, and attractor landscapes that constrain where development can go. The second applies this framework to classical birth defects — cleft palate, spina bifida, polydactyly, congenital heart malformations — recasting each as a specific class of geometry failure. The third extends the analysis to autism-spectrum conditions, arguing that ASC is not brain damage but a systematic field-mapping difference: the cortical field resolved to an adjacent attractor state, producing a genuinely different cognitive geometry rather than a broken one. The fourth addresses the most severe structural malformations — holoprosencephaly, gastroschisis, diaphragmatic hernia — as topological failures, cases where the field could not complete a required discontinuous transition in shape. We close by drawing out the therapeutic implications: a medicine that reads development as field-geometry will intervene at the level of the field — restoring gradients, correcting attractor landscapes, timing interventions to transition windows — rather than chasing isolated molecules in isolation from the geometry that gives them meaning. Every paper in this DOI is its own stand‑alone piece. They’re not drafts, not rewrites, not alternate takes, they’re different subjects, each teaching biology using the new understanding that came out of the UST physics breakthrough. One paper explains how electrical fields organize living tissue. Another shows how autoimmune disease starts when that architecture fails. Another breaks down screening. Another covers treatment logic. Others go deeper into development, regeneration, aging, or organ‑level field behavior. Each one is a separate tool: a teaching tool for biology, a research tool for scientists, and a conceptual tool for building new ways to diagnose and treat disease. Together they form a library built on UST, a physics discovery that rewrites how biology actually works and opens the door to curing autoimmune disease and, eventually, every disease built on structural failure. If you have questions or want to discuss the work, you can contact me directly at dustin@unifiedsubstratetheory.com Don't be shy. I want to discuss science. It is fun and should be. Reachout and lets get started on new discoveries.
2026-04-03 | Sonic Hedgehog in Neural Tube Patterning: From Morphogen Gradient to Therapeutic Target
This document synthesizes current knowledge on the Sonic Hedgehog (SHH) signaling pathway, establishing it as a quintessential morphogen that orchestrates the patterning of the ventral neural tube according to the French Flag model. Secreted from the notochord and floor plate, SHH forms a precise concentration gradient that instructs neural progenitor cells to adopt distinct fates, such as motor neurons and various interneurons, based on both the concentration and duration of exposure. The canonical signaling cascade is detailed, from the dual-lipid modification of the SHH ligand to its binding of the Patched1 (PTCH1) receptor, which relieves inhibition of Smoothened (SMO). Activated SMO then accumulates in the primary cilium, initiating a signal that prevents the proteolytic processing of GLI transcription factors into repressors, thereby promoting their activator forms to regulate target gene expression. A significant recent discovery discussed is the functional partitioning of SHH signaling through its secretion on biochemically distinct exosomal pools. A dense vesicle fraction, Shh-P150, mediates canonical patterning, while a lighter pool, Shh-P450, drives progenitor proliferation via a non-canonical, Gαi-dependent pathway. This mechanism explains how a single morphogen can direct disparate cellular outcomes. The article thoroughly explores the pathological implications of pathway dysregulation, linking insufficient signaling to congenital disorders like holoprosencephaly and aberrant reactivation to cancers, including medulloblastoma and basal cell carcinoma. This has led to the development of targeted therapies, primarily SMO inhibitors like vismodegib and sonidegib. However, their clinical efficacy is hampered by on-target toxicity and the emergence of drug resistance through SMO mutations or downstream pathway activation. Source: https://www.devbiosci.com/posts/sonic-hedgehog-in-neural-tube-patterning-from-morphogen-gradient-to-therapeutic-target
2026-03-30 | Methyldopa as a novel therapeutic option for paroxysmal sympathetic hyperactivity in pediatric patients: A case report
Background Paroxysmal sympathetic hyperactivity (PSH) is a clinical syndrome characterized by intermittent episodes of excessive sympathetic and motor activity, including tachycardia, hypertension, hyperthermia, tachypnea, excessive diaphoresis, and abnormal posturing. Clonidine, an α2-adrenergic agonist, is used as a treatment for PSH, demonstrating efficacy across multiple studies. However, market withdrawal and the lack of a generic alternative in Japan have prompted the need for other therapeutic options. Case presentations Case 1 was 2-year-old boy with trisomy 13 complicated by holoprosencephaly, severe intellectual disability, and mixed quadriplegia. His PSH had been well-controlled with clonidine, which was successfully replaced with methyldopa after discontinuation of the former. Case 2 was a 1-year-old boy diagnosed with early infantile epileptic encephalopathy caused by a KCNQ2 mutation. PSH symptoms and elevated creatine kinase levels were alleviated with gabapentin and methyldopa. Discussion and conclusion We present the first two pediatric cases of PSH successfully managed with methyldopa, another α2-adrenergic agonist, as an alternative to clonidine. Methyldopa may serve as a promising alternative treatment for pediatric patients with PSH, particularly in settings where clonidine is unavailable. Further studies are required to evaluate the efficacy, safety, and long-term outcomes of methyldopa in this population.
2026-01-25 | Daily use of buccal midazolam for refractory seizures in an infant with holoprosencephaly: A case report
We report the case of an infant with alobar holoprosencephaly with drug-resistant severe epilepsy. Due to a heavy seizure burden, frequent use of buccal midazolam was attempted, and the seizures and associated sleep disturbances were effectively controlled without major adverse events. The patient was a female infant with alobar holoprosencephaly. At 60 days of age, she experienced clinical seizures with eye deviation, oral automatism, and clonic limb movements that rapidly worsened to frequent and prolonged seizures. Intravenous phenobarbital temporarily suppressed the seizures but caused prolonged sedation and feeding difficulty. Several oral anti-seizure medications were ineffective. We introduced the frequent, nightly repeated use of buccal midazolam for status epilepticus, leading to seizure-free intervals, better nutrition, and the establishment of sleep-wake cycles. No significant adverse effects were observed, including respiratory suppression. Frequent use of buccal midazolam not only reduced the seizure burden but also improved sleep and nutrition related to seizures in a patient with holoprosencephaly.
proteins
2024-07-17 | Pulsatile gonadotropin-releasing hormone therapy induces spermatogenesis in pituitary stalk interruption syndrome: A case report and review of the literature.
Pituitary stalk interruption syndrome (PSIS) is a rare anatomical defect of the pituitary gland falling under the spectrum of holoprosencephaly phenotypes. It is characterized by a deficiency in anterior pituitary hormones, such as growth hormone, gonadotropins, and thyroid hormones. Due to the syndrome's rarity and nonspecific manifestations, there is a lack of standardized treatment strategies. Consequently, early diagnosis through imaging and on-time intervention are crucial for improving patients' outcomes. A 30-year-old man presented with absent secondary sexual characteristics and azoospermia. Laboratory evaluation revealed a deficiency in gonadotropins, while thyroid function was mostly within normal ranges. Magnetic resonance imaging of the pituitary gland showed pituitary stalk agenesis, hypoplasia of the anterior pituitary, and ectopic posterior pituitary, leading to the diagnosis of PSIS. Initially, the patient underwent 6 mo of gonadotropin therapy without significant changes in hormone levels and secondary sexual characteristics. Pulsatile gonadotropin-releasing hormone therapy was then administered, resulting in the detection of sperm in the semen analysis within 3 mo. After 6 mo, routine semen tests showed normal semen quality. The couple faced challenges in conceiving due to abstinence and underwent three cycles of artificial insemination, which was unsuccessful. They also attempted in vitro fertilization, but unfortunately, the woman experienced a miscarriage 10 wk after the embryo transfer. Early detection, accurate diagnosis, and timely treatment are crucial in improving the quality of life and fertility of PSIS patients.
2024-07-09 | Effects of GLP1 receptor analogues in obesity with neurodevelopmental disorder: case report of a patient with holoprosencephaly.
Holoprosencephaly is an anomaly in the division of the prosencephalon into cerebral hemispheres during the second month of gestation. Patients can present with early-onset obesity favoured by the cognitive impairment. We present a case of a 24 year-old woman with holoprosencephaly and class III obesity who was treated by 2.4 mg/week SEMAGLUTIDE. Her body weight decreased from 115.3 to 94.3 kg after one-year (18% of total body weight loss). In addition, she presented a marked reduction in self- and hetero-aggressive behaviour when exposed to the sight of food. The treatment was well tolerated, with the exception of a few vomiting when eating palatable food too quickly. GLP1-RAs may be interesting for obesity treatment in the context of neurodevelopmental disorders. They appear to reduce compulsive eating and aggressive behaviour, particularly in relation to exposure to food, and lead to weight loss similar to that seen in people without neurodevelopmental disorders.
2022-12-01 | Early eye and forebrain development are facilitated by Bone Morphogenetic Protein antagonism
Abstract Vision likely is our most prominent sense and a correct development of the eye is at its basis. Early eye development is tightly connected to the development of the forebrain. A single eye field and the prospective telencephalon are situated within the anterior neural plate (ANP). If development is running correctly both are split and consecutively two optic vesicles and two telencephalic lobes emerge. If hampered, the domain is remaining condensed at the midline. This affection of development is termed Holoprosencephaly (HPE). The classical ocular finding associated with intense forms of HPE is cyclopia, one central eye. We found that antagonists of Bone morphogenetic proteins (BMP) are important to facilitate proper forebrain and eye field cleavage. Experimental induction of a BMP ligand results in HPE and the analyses of the ANP indicated a severe form. We further found anophthalmia instead of cyclopia associated with the present HPE phenotype. We identified retinal progenitors stuck in the forebrain domain, which we termed crypt-oculoid. Our data further suggest that the process of basal constriction of retinal progenitors is hampered by elevated levels of the BMP ligand. This likely is the reason for anophthalmia instead of cyclopia in this present case of HPE.
2018-09-11 | Hypothalamic sonic hedgehog is required for cell specification and proliferation of LHX3/LHX4 pituitary embryonic precursors
Aberrant development of the anterior pituitary can lead to congenital hypopituitarism (CH) in humans and hence understanding how this organ develops is critical to understand CH. The anterior pituitary develops in intimate contact with the prospective hypothalamus, which secretes growth factors that are required for the pituitary gland to grow. In this elegant paper, from Martinez-Barbera’s laboratory, they utilise a mouse transgenic line, Hesx1Cre/+ to either delete or activate Shh pathway, which is known be important for midline development. By deleting Shh from the anterior hypothalamus, the authors show that Shh signalling in this tissue is critical for Rathke’s pouch induction, hence dissecting out the role of this signalling during early development. Mutations in hSHH lead to holoprosencephaly, a severe middle defect that can been linked to congenital hypopituitarism. Indeed mutations in downstream effectors of SHH, such as GLI2, lead to CH with brain abnormalities in humans, demonstrating the clinical importance of components of this pathway in pituitary disease. How Shh activates or induces Lhx3/Lhx4 in pituitary precursors remains unknown, but this work clearly shows that it acts upstream of these factors. Therefore, Shh secreting molecules could also potentially be used in stem cell differentiation protocols to differentiate progenitor cells into Lhx3/Lhx4 RP progenitors.
2018-01-24 | Rare Disease: Lobar Holoprosencephaly With a Median Cleft Lip-Case Report.
Holoprosencephaly is a complex malformation of the brain associated with the median facial defects. Variability of the clinical picture is the characteristic of this anomaly. In most cases, the degree of severity of the facial anomaly correlates with the degree of damage to the brain. This article aims to present a rare case of child with a milder form of brain anomaly combined with a severe form of facial anomaly. The article also presents the application of a feeding stimulator to improve the child's quality of life. The anomaly was diagnosed by postnatal sonography of the brain, magnetic resonance imaging of the endocranium, and three-dimensional computed tomography of the craniofacial skeleton.
gene therapies
2026-06-08 | Semilobar holoprosencephaly associated with maternal diabetes in a toddler: A case report.
Holoprosencephaly is a rare congenital malformation of the forebrain caused by incomplete division of the prosencephalon during early embryonic development, and semilobar holoprosencephaly represents the intermediate form of the spectrum. We report the case of a 3-year-old child presenting with developmental delay, seizures, feeding difficulties, and midline facial abnormalities. The child was born to a mother with poorly controlled maternal diabetes mellitus. The MRI scan of the brain showed partial fusion of the frontal lobes, incomplete separation of the hemispheres of the cerebrum, presence of a single ventricular cavity, partial fusion of the thalami, and lack of the septum pellucidum. These clinical signs suggested semilobar holoprosencephaly. This case underlines the importance of neuroimaging in evaluating children with developmental delay and neurological symptoms, and early recognition of such malformations may contribute to better clinical follow-up and family guidance.
2026-04-13 | Face Predicts the Brain: Prenatal Ultrasound Diagnosis of Alobar Holoprosencephaly with Multisystem Anomalies - A Rare Case Report
Holoprosencephaly is a rare congenital malformation resulting from incomplete cleavage of the forebrain and is frequently associated with severe craniofacial and systemic anomalies. We present a case of a 16-week intrauterine fetus diagnosed on antenatal ultrasonography with alobar holoprosencephaly and multiple associated anomalies. Ultrasound revealed a monoventricle with fused thalami, absent midline structures, and severe facial dysmorphism including absent orbits and a midline proboscis. Associated findings included a cystic lesion suggestive of a foregut duplication cyst, complex congenital heart disease, and bilateral echogenic kidneys. These findings indicate a poor prognosis and are highly suggestive of a syndromic association, most commonly trisomy 13.
2025-12-30 | The importance of mid-trimester anomaly scans in a low-resource setting: a retrospective study of 7,615 mid-trimester anomaly scans at a tertiary maternity hospital in Nepal
Background Congenital anomalies are a leading cause of perinatal mortality in low- and middle-income countries. While mid-trimester anomaly scans are standard in high-income settings, their utility in Nepal remains undocumented. This study evaluates the spectrum, frequency, and clinical significance of fetal anomalies detected during routine anomaly scans at Nepal’s largest maternity hospital. Methods A retrospective cross-sectional study was conducted at Paropakar Maternity and Women’s Hospital (PMWH), analyzing all mid-trimester anomaly scans (18–24 weeks) performed between January 2021 and April 2023. Anomalies were classified as major (structurally significant) or minor/soft markers (e.g., echogenic bowel, intracardiac echogenic focus). Data were summarized using descriptive statistics, and associations were assessed using Chi-square test. Results Of 7,615 anomaly scans, 2,807 (36.9%) detected at least one anomaly. The most common findings were hydronephrosis (27.1%), echogenic bowel (21.4%), and central nervous system variants (26.1%). Only 88 (3.1%) were major anomalies, including neural tube defects (n = 8), holoprosencephaly (n = 2), omphalocele, gastroschisis, and skeletal dysplasia. Soft markers were present in 1,380 (49.2%) of all anomaly cases. Critically, 68 (81.0%) of 84 major anomalies occurred in fetuses with ≥ 1 soft marker, compared to only 16 without. This association was highly significant (χ² = 42.6, p < 0.001; OR = 4.6, 95% CI: 2.6–8.1). Conclusions Mid-trimester anomaly scans in Nepal detect a substantial number of clinically significant fetal anomalies. The strong association between soft markers and major structural defects underscores their value as screening indicators, even in settings where advanced diagnostics are unavailable. These findings support the integration of standardized anomaly scans into routine antenatal care across similar low-resource regions.
2017-10-01 | Three Tctn proteins are functionally conserved in the regulation of neural tube patterning and Gli3 processing but not ciliogenesis and Hedgehog signaling in the mouse
Tctn1, Tctn2, and Tctn3 are membrane proteins that localize at the transition zone of primary cilia. Tctn1 and Tctn2 mutations have been reported in both humans and mice, but Tctn3 mutations have been reported only in humans. It is also not clear whether the three Tctn proteins are functionally conserved with respect to ciliogenesis and Hedgehog (Hh) signaling. In the present study, we report that loss of Tctn3 gene function in mice results in a decrease in ciliogenesis and Hh signaling. Consistent with this, Tctn3 mutant mice exhibit holoprosencephaly and randomized heart looping and lack the floor plate in the neural tube, the phenotypes similar to those of Tctn1 and Tctn2 mutants. We also show that overexpression of Tctn3, but not Tctn1 or Tctn2, can rescue ciliogenesis in Tctn3 mutant cells. Similarly, replacement of Tctn3 with Tctn1 or Tctn2 in the Tctn3 gene locus results in reduced ciliogenesis and Hh signaling, holoprosencephaly, and randomized heart looping. Surprisingly, however, the neural tube patterning and the proteolytic processing of Gli3 (a transcription regulator for Hh signaling) into a repressor, both of which are usually impaired in ciliary gene mutants, are normal. These results suggest that Tctn1, Tctn2, and Tctn3 are functionally divergent with respect to their role in ciliogenesis and Hh signaling but conserved in neural tube patterning and Gli3 processing.
2016-07-27 | Zic2 mutation causes holoprosencephaly via disruption of NODAL signalling.
The ZIC2 transcription factor is one of the genes most commonly mutated in Holoprosencephaly (HPE) probands. Studies in cultured cell lines and mice have shown a loss of ZIC2 function is the pathogenic mechanism but the molecular details of this ZIC2 requirement remain elusive. HPE arises when signals that direct morphological and fate changes in the developing brain and facial primordia are not sent or received. One critical signal is sent from the prechordal plate (PrCP) which develops beneath the ventral forebrain. An intact NODAL signal transduction pathway and functional ZIC2 are both required for PrCP establishment. We now show that ZIC2 acts downstream of the NODAL signal during PrCP development. ZIC2 physically interacts with SMAD2 and SMAD3, the receptor activated proteins that control transcription in a NODAL dependent manner. Together SMAD3 and ZIC2 regulate FOXA2 transcription in cultured cells and Zic2 also controls the foxA2 expression during Xenopus development. Variant forms of the ZIC2 protein, associated with HPE in man or mouse, are deficient in their ability to influence SMAD-dependent transcription. These findings reveal a new mechanism of NODAL signal transduction in the mammalian node and provide the first molecular explanation of how ZIC2 loss-of-function precipitates HPE.
cell therapies
2025-06-19 | Surgical Nuances in Ultrasound-Guided Percutaneous Distal Catheter Placement in Pediatric Ventriculoatrial Shunts.
Currently, there is no universally accepted consensus regarding the optimal site for distal catheter placement in patients with congenital hydrocephalus and a non-functional peritoneal cavity, as therapeutic strategies must be meticulously individualized based on each patient's unique anatomical and physiological considerations. We report a complex case involving a one-year-old male infant, born prematurely, with alobar holoprosencephaly (HPE) and congenital hydrocephalus, who experienced multiple ventriculoperitoneal shunt (VPS) failures. These complications were attributed to impaired peritoneal absorption of cerebrospinal fluid (CSF), recurrent shunt infections, and occlusion of an external ventricular drainage system. As a salvage intervention, a ventriculoatrial shunt (VAS) was successfully established using ultrasound-guided internal jugular vein cannulation, followed by fluoroscopy-assisted endovascular placement of a modified distal catheter via the Seldinger technique. This approach underscores the utility of image-guided VAS as a viable alternative in cases of VPS failure secondary to peritoneal CSF resorption insufficiency, particularly in patients with complex neuroanatomical profiles.
2023-09-08 | Alobar holoprosencephaly: A case report
Introduction: Holoprosencephaly (HPE) is a rare brain malformation, which results from a cleavage defect of the prosencephalon. Three forms have been described as: alobar, semi-lobar, and lobar forms. Case Report: We report a rare case of holoprosencephaly, diagnosed at the maternity of the Ibn Rochd Hospital Center in Casablanca. Conclusion: Holoprosencephaly is secondary to a cleavage anomaly of the prosencephalon, the diagnosis is based on echotomography, computed tomography (CT) scan and nuclear magnetic resonance imaging (MRI). It is important to perform a karyotype to look for a chromosomal anomaly. Holoprosencephaly, although rare, should be recognized and diagnosed; minor forms are likely to benefit from medical replacement therapy or ventricular shunting.
small molecules
2026-06-30 | Chorea misinterpreted as agitation in a 15-month-old girl with semilobar holoprosencephaly: a case report
We report the case of a 15-month-old girl with semilobar holoprosencephaly, microcephaly, central diabetes insipidus, failure to thrive, and severe global developmental delay who was admitted to the pediatric intensive care unit for aspiration pneumonia requiring mechanical ventilation.Caregivers reported long-standing severe irritability and poor sleep, for which she had been taking melatonin and diazepam before admission.During ventilator weaning, persistent irritability, irregular breathing, and excessive nonrhythmic movements were repeatedly interpreted as agitation, leading to increased analgesic and sedative requirements, including sufentanil and midazolam infusions and intermittent rescue chloral hydrate, and contributing to a prolonged ventilatory course.The movements were involuntary and irregular, worsened during wakefulness, and resolved during sleep.Electroencephalography revealed no electrographic seizures or epileptiform discharges and showed a poorly organized background consistent with the underlying structural brain disease.After chorea was suspected, pediatric neurology was consulted.Additional caregiver history suggested that similar involuntary movements had occurred before admission and may have contributed to her long-standing irritability and poor sleep.Treatment with clonazepam and dopamine receptor antagonists, including haloperidol and risperidone, reduced the movements and improved clinical stability, enabling transfer to the ward and subsequent discharge.This case illustrates that chorea may be mistaken for agitation in neurologically impaired infants or toddlers and that careful observation of the movement pattern, including suppression during sleep, may facilitate recognition and limit unnecessary escalation of sedation.
2026-06-17 | Congenital and Developmental Disorders: A Field-Geometry Account
Development is not the execution of a genetic program. It is a field-geometry process — one in which the embryo functions as a self-organizing tensor field that reads positional information, resolves chemical and mechanical gradients, and locks into stable configurations we recognize as organs, limbs, bones, and neural circuits. In this framework, the genome does not specify anatomy any more than a tuning dial specifies the music coming out of a radio. Genes tune the field. The field makes the shape. Congenital and developmental disorders, viewed through this lens, are not random errors in a recipe. They are geometry-drift events: instances where the morphogenetic field resolved to a wrong attractor, failed to complete a topological transition, or operated on corrupted positional-information gradients. This manuscript develops that argument across four interlocking pillars. The first establishes the conceptual foundation: morphogenesis is a field-geometry phenomenon, governed by reaction-diffusion dynamics, gradient superposition, mechanical stress fields, and attractor landscapes that constrain where development can go. The second applies this framework to classical birth defects — cleft palate, spina bifida, polydactyly, congenital heart malformations — recasting each as a specific class of geometry failure. The third extends the analysis to autism-spectrum conditions, arguing that ASC is not brain damage but a systematic field-mapping difference: the cortical field resolved to an adjacent attractor state, producing a genuinely different cognitive geometry rather than a broken one. The fourth addresses the most severe structural malformations — holoprosencephaly, gastroschisis, diaphragmatic hernia — as topological failures, cases where the field could not complete a required discontinuous transition in shape. We close by drawing out the therapeutic implications: a medicine that reads development as field-geometry will intervene at the level of the field — restoring gradients, correcting attractor landscapes, timing interventions to transition windows — rather than chasing isolated molecules in isolation from the geometry that gives them meaning. Every paper in this DOI is its own stand‑alone piece. They’re not drafts, not rewrites, not alternate takes, they’re different subjects, each teaching biology using the new understanding that came out of the UST physics breakthrough. One paper explains how electrical fields organize living tissue. Another shows how autoimmune disease starts when that architecture fails. Another breaks down screening. Another covers treatment logic. Others go deeper into development, regeneration, aging, or organ‑level field behavior. Each one is a separate tool: a teaching tool for biology, a research tool for scientists, and a conceptual tool for building new ways to diagnose and treat disease. Together they form a library built on UST, a physics discovery that rewrites how biology actually works and opens the door to curing autoimmune disease and, eventually, every disease built on structural failure. If you have questions or want to discuss the work, you can contact me directly at dustin@unifiedsubstratetheory.com Don't be shy. I want to discuss science. It is fun and should be. Reachout and lets get started on new discoveries.
2026-04-03 | Sonic Hedgehog in Neural Tube Patterning: From Morphogen Gradient to Therapeutic Target
This document synthesizes current knowledge on the Sonic Hedgehog (SHH) signaling pathway, establishing it as a quintessential morphogen that orchestrates the patterning of the ventral neural tube according to the French Flag model. Secreted from the notochord and floor plate, SHH forms a precise concentration gradient that instructs neural progenitor cells to adopt distinct fates, such as motor neurons and various interneurons, based on both the concentration and duration of exposure. The canonical signaling cascade is detailed, from the dual-lipid modification of the SHH ligand to its binding of the Patched1 (PTCH1) receptor, which relieves inhibition of Smoothened (SMO). Activated SMO then accumulates in the primary cilium, initiating a signal that prevents the proteolytic processing of GLI transcription factors into repressors, thereby promoting their activator forms to regulate target gene expression. A significant recent discovery discussed is the functional partitioning of SHH signaling through its secretion on biochemically distinct exosomal pools. A dense vesicle fraction, Shh-P150, mediates canonical patterning, while a lighter pool, Shh-P450, drives progenitor proliferation via a non-canonical, Gαi-dependent pathway. This mechanism explains how a single morphogen can direct disparate cellular outcomes. The article thoroughly explores the pathological implications of pathway dysregulation, linking insufficient signaling to congenital disorders like holoprosencephaly and aberrant reactivation to cancers, including medulloblastoma and basal cell carcinoma. This has led to the development of targeted therapies, primarily SMO inhibitors like vismodegib and sonidegib. However, their clinical efficacy is hampered by on-target toxicity and the emergence of drug resistance through SMO mutations or downstream pathway activation. Source: https://www.devbiosci.com/posts/sonic-hedgehog-in-neural-tube-patterning-from-morphogen-gradient-to-therapeutic-target
2026-03-30 | Methyldopa as a novel therapeutic option for paroxysmal sympathetic hyperactivity in pediatric patients: A case report
Background Paroxysmal sympathetic hyperactivity (PSH) is a clinical syndrome characterized by intermittent episodes of excessive sympathetic and motor activity, including tachycardia, hypertension, hyperthermia, tachypnea, excessive diaphoresis, and abnormal posturing. Clonidine, an α2-adrenergic agonist, is used as a treatment for PSH, demonstrating efficacy across multiple studies. However, market withdrawal and the lack of a generic alternative in Japan have prompted the need for other therapeutic options. Case presentations Case 1 was 2-year-old boy with trisomy 13 complicated by holoprosencephaly, severe intellectual disability, and mixed quadriplegia. His PSH had been well-controlled with clonidine, which was successfully replaced with methyldopa after discontinuation of the former. Case 2 was a 1-year-old boy diagnosed with early infantile epileptic encephalopathy caused by a KCNQ2 mutation. PSH symptoms and elevated creatine kinase levels were alleviated with gabapentin and methyldopa. Discussion and conclusion We present the first two pediatric cases of PSH successfully managed with methyldopa, another α2-adrenergic agonist, as an alternative to clonidine. Methyldopa may serve as a promising alternative treatment for pediatric patients with PSH, particularly in settings where clonidine is unavailable. Further studies are required to evaluate the efficacy, safety, and long-term outcomes of methyldopa in this population.
2026-01-25 | Daily use of buccal midazolam for refractory seizures in an infant with holoprosencephaly: A case report
We report the case of an infant with alobar holoprosencephaly with drug-resistant severe epilepsy. Due to a heavy seizure burden, frequent use of buccal midazolam was attempted, and the seizures and associated sleep disturbances were effectively controlled without major adverse events. The patient was a female infant with alobar holoprosencephaly. At 60 days of age, she experienced clinical seizures with eye deviation, oral automatism, and clonic limb movements that rapidly worsened to frequent and prolonged seizures. Intravenous phenobarbital temporarily suppressed the seizures but caused prolonged sedation and feeding difficulty. Several oral anti-seizure medications were ineffective. We introduced the frequent, nightly repeated use of buccal midazolam for status epilepticus, leading to seizure-free intervals, better nutrition, and the establishment of sleep-wake cycles. No significant adverse effects were observed, including respiratory suppression. Frequent use of buccal midazolam not only reduced the seizure burden but also improved sleep and nutrition related to seizures in a patient with holoprosencephaly.
proteins
2024-07-17 | Pulsatile gonadotropin-releasing hormone therapy induces spermatogenesis in pituitary stalk interruption syndrome: A case report and review of the literature.
Pituitary stalk interruption syndrome (PSIS) is a rare anatomical defect of the pituitary gland falling under the spectrum of holoprosencephaly phenotypes. It is characterized by a deficiency in anterior pituitary hormones, such as growth hormone, gonadotropins, and thyroid hormones. Due to the syndrome's rarity and nonspecific manifestations, there is a lack of standardized treatment strategies. Consequently, early diagnosis through imaging and on-time intervention are crucial for improving patients' outcomes. A 30-year-old man presented with absent secondary sexual characteristics and azoospermia. Laboratory evaluation revealed a deficiency in gonadotropins, while thyroid function was mostly within normal ranges. Magnetic resonance imaging of the pituitary gland showed pituitary stalk agenesis, hypoplasia of the anterior pituitary, and ectopic posterior pituitary, leading to the diagnosis of PSIS. Initially, the patient underwent 6 mo of gonadotropin therapy without significant changes in hormone levels and secondary sexual characteristics. Pulsatile gonadotropin-releasing hormone therapy was then administered, resulting in the detection of sperm in the semen analysis within 3 mo. After 6 mo, routine semen tests showed normal semen quality. The couple faced challenges in conceiving due to abstinence and underwent three cycles of artificial insemination, which was unsuccessful. They also attempted in vitro fertilization, but unfortunately, the woman experienced a miscarriage 10 wk after the embryo transfer. Early detection, accurate diagnosis, and timely treatment are crucial in improving the quality of life and fertility of PSIS patients.
2024-07-09 | Effects of GLP1 receptor analogues in obesity with neurodevelopmental disorder: case report of a patient with holoprosencephaly.
Holoprosencephaly is an anomaly in the division of the prosencephalon into cerebral hemispheres during the second month of gestation. Patients can present with early-onset obesity favoured by the cognitive impairment. We present a case of a 24 year-old woman with holoprosencephaly and class III obesity who was treated by 2.4 mg/week SEMAGLUTIDE. Her body weight decreased from 115.3 to 94.3 kg after one-year (18% of total body weight loss). In addition, she presented a marked reduction in self- and hetero-aggressive behaviour when exposed to the sight of food. The treatment was well tolerated, with the exception of a few vomiting when eating palatable food too quickly. GLP1-RAs may be interesting for obesity treatment in the context of neurodevelopmental disorders. They appear to reduce compulsive eating and aggressive behaviour, particularly in relation to exposure to food, and lead to weight loss similar to that seen in people without neurodevelopmental disorders.
2022-12-01 | Early eye and forebrain development are facilitated by Bone Morphogenetic Protein antagonism
Abstract Vision likely is our most prominent sense and a correct development of the eye is at its basis. Early eye development is tightly connected to the development of the forebrain. A single eye field and the prospective telencephalon are situated within the anterior neural plate (ANP). If development is running correctly both are split and consecutively two optic vesicles and two telencephalic lobes emerge. If hampered, the domain is remaining condensed at the midline. This affection of development is termed Holoprosencephaly (HPE). The classical ocular finding associated with intense forms of HPE is cyclopia, one central eye. We found that antagonists of Bone morphogenetic proteins (BMP) are important to facilitate proper forebrain and eye field cleavage. Experimental induction of a BMP ligand results in HPE and the analyses of the ANP indicated a severe form. We further found anophthalmia instead of cyclopia associated with the present HPE phenotype. We identified retinal progenitors stuck in the forebrain domain, which we termed crypt-oculoid. Our data further suggest that the process of basal constriction of retinal progenitors is hampered by elevated levels of the BMP ligand. This likely is the reason for anophthalmia instead of cyclopia in this present case of HPE.
2018-09-11 | Hypothalamic sonic hedgehog is required for cell specification and proliferation of LHX3/LHX4 pituitary embryonic precursors
Aberrant development of the anterior pituitary can lead to congenital hypopituitarism (CH) in humans and hence understanding how this organ develops is critical to understand CH. The anterior pituitary develops in intimate contact with the prospective hypothalamus, which secretes growth factors that are required for the pituitary gland to grow. In this elegant paper, from Martinez-Barbera’s laboratory, they utilise a mouse transgenic line, Hesx1Cre/+ to either delete or activate Shh pathway, which is known be important for midline development. By deleting Shh from the anterior hypothalamus, the authors show that Shh signalling in this tissue is critical for Rathke’s pouch induction, hence dissecting out the role of this signalling during early development. Mutations in hSHH lead to holoprosencephaly, a severe middle defect that can been linked to congenital hypopituitarism. Indeed mutations in downstream effectors of SHH, such as GLI2, lead to CH with brain abnormalities in humans, demonstrating the clinical importance of components of this pathway in pituitary disease. How Shh activates or induces Lhx3/Lhx4 in pituitary precursors remains unknown, but this work clearly shows that it acts upstream of these factors. Therefore, Shh secreting molecules could also potentially be used in stem cell differentiation protocols to differentiate progenitor cells into Lhx3/Lhx4 RP progenitors.
2018-01-24 | Rare Disease: Lobar Holoprosencephaly With a Median Cleft Lip-Case Report.
Holoprosencephaly is a complex malformation of the brain associated with the median facial defects. Variability of the clinical picture is the characteristic of this anomaly. In most cases, the degree of severity of the facial anomaly correlates with the degree of damage to the brain. This article aims to present a rare case of child with a milder form of brain anomaly combined with a severe form of facial anomaly. The article also presents the application of a feeding stimulator to improve the child's quality of life. The anomaly was diagnosed by postnatal sonography of the brain, magnetic resonance imaging of the endocranium, and three-dimensional computed tomography of the craniofacial skeleton.
gene therapies
2026-06-08 | Semilobar holoprosencephaly associated with maternal diabetes in a toddler: A case report.
Holoprosencephaly is a rare congenital malformation of the forebrain caused by incomplete division of the prosencephalon during early embryonic development, and semilobar holoprosencephaly represents the intermediate form of the spectrum. We report the case of a 3-year-old child presenting with developmental delay, seizures, feeding difficulties, and midline facial abnormalities. The child was born to a mother with poorly controlled maternal diabetes mellitus. The MRI scan of the brain showed partial fusion of the frontal lobes, incomplete separation of the hemispheres of the cerebrum, presence of a single ventricular cavity, partial fusion of the thalami, and lack of the septum pellucidum. These clinical signs suggested semilobar holoprosencephaly. This case underlines the importance of neuroimaging in evaluating children with developmental delay and neurological symptoms, and early recognition of such malformations may contribute to better clinical follow-up and family guidance.
2026-04-13 | Face Predicts the Brain: Prenatal Ultrasound Diagnosis of Alobar Holoprosencephaly with Multisystem Anomalies - A Rare Case Report
Holoprosencephaly is a rare congenital malformation resulting from incomplete cleavage of the forebrain and is frequently associated with severe craniofacial and systemic anomalies. We present a case of a 16-week intrauterine fetus diagnosed on antenatal ultrasonography with alobar holoprosencephaly and multiple associated anomalies. Ultrasound revealed a monoventricle with fused thalami, absent midline structures, and severe facial dysmorphism including absent orbits and a midline proboscis. Associated findings included a cystic lesion suggestive of a foregut duplication cyst, complex congenital heart disease, and bilateral echogenic kidneys. These findings indicate a poor prognosis and are highly suggestive of a syndromic association, most commonly trisomy 13.
2025-12-30 | The importance of mid-trimester anomaly scans in a low-resource setting: a retrospective study of 7,615 mid-trimester anomaly scans at a tertiary maternity hospital in Nepal
Background Congenital anomalies are a leading cause of perinatal mortality in low- and middle-income countries. While mid-trimester anomaly scans are standard in high-income settings, their utility in Nepal remains undocumented. This study evaluates the spectrum, frequency, and clinical significance of fetal anomalies detected during routine anomaly scans at Nepal’s largest maternity hospital. Methods A retrospective cross-sectional study was conducted at Paropakar Maternity and Women’s Hospital (PMWH), analyzing all mid-trimester anomaly scans (18–24 weeks) performed between January 2021 and April 2023. Anomalies were classified as major (structurally significant) or minor/soft markers (e.g., echogenic bowel, intracardiac echogenic focus). Data were summarized using descriptive statistics, and associations were assessed using Chi-square test. Results Of 7,615 anomaly scans, 2,807 (36.9%) detected at least one anomaly. The most common findings were hydronephrosis (27.1%), echogenic bowel (21.4%), and central nervous system variants (26.1%). Only 88 (3.1%) were major anomalies, including neural tube defects (n = 8), holoprosencephaly (n = 2), omphalocele, gastroschisis, and skeletal dysplasia. Soft markers were present in 1,380 (49.2%) of all anomaly cases. Critically, 68 (81.0%) of 84 major anomalies occurred in fetuses with ≥ 1 soft marker, compared to only 16 without. This association was highly significant (χ² = 42.6, p < 0.001; OR = 4.6, 95% CI: 2.6–8.1). Conclusions Mid-trimester anomaly scans in Nepal detect a substantial number of clinically significant fetal anomalies. The strong association between soft markers and major structural defects underscores their value as screening indicators, even in settings where advanced diagnostics are unavailable. These findings support the integration of standardized anomaly scans into routine antenatal care across similar low-resource regions.
2017-10-01 | Three Tctn proteins are functionally conserved in the regulation of neural tube patterning and Gli3 processing but not ciliogenesis and Hedgehog signaling in the mouse
Tctn1, Tctn2, and Tctn3 are membrane proteins that localize at the transition zone of primary cilia. Tctn1 and Tctn2 mutations have been reported in both humans and mice, but Tctn3 mutations have been reported only in humans. It is also not clear whether the three Tctn proteins are functionally conserved with respect to ciliogenesis and Hedgehog (Hh) signaling. In the present study, we report that loss of Tctn3 gene function in mice results in a decrease in ciliogenesis and Hh signaling. Consistent with this, Tctn3 mutant mice exhibit holoprosencephaly and randomized heart looping and lack the floor plate in the neural tube, the phenotypes similar to those of Tctn1 and Tctn2 mutants. We also show that overexpression of Tctn3, but not Tctn1 or Tctn2, can rescue ciliogenesis in Tctn3 mutant cells. Similarly, replacement of Tctn3 with Tctn1 or Tctn2 in the Tctn3 gene locus results in reduced ciliogenesis and Hh signaling, holoprosencephaly, and randomized heart looping. Surprisingly, however, the neural tube patterning and the proteolytic processing of Gli3 (a transcription regulator for Hh signaling) into a repressor, both of which are usually impaired in ciliary gene mutants, are normal. These results suggest that Tctn1, Tctn2, and Tctn3 are functionally divergent with respect to their role in ciliogenesis and Hh signaling but conserved in neural tube patterning and Gli3 processing.
2016-07-27 | Zic2 mutation causes holoprosencephaly via disruption of NODAL signalling.
The ZIC2 transcription factor is one of the genes most commonly mutated in Holoprosencephaly (HPE) probands. Studies in cultured cell lines and mice have shown a loss of ZIC2 function is the pathogenic mechanism but the molecular details of this ZIC2 requirement remain elusive. HPE arises when signals that direct morphological and fate changes in the developing brain and facial primordia are not sent or received. One critical signal is sent from the prechordal plate (PrCP) which develops beneath the ventral forebrain. An intact NODAL signal transduction pathway and functional ZIC2 are both required for PrCP establishment. We now show that ZIC2 acts downstream of the NODAL signal during PrCP development. ZIC2 physically interacts with SMAD2 and SMAD3, the receptor activated proteins that control transcription in a NODAL dependent manner. Together SMAD3 and ZIC2 regulate FOXA2 transcription in cultured cells and Zic2 also controls the foxA2 expression during Xenopus development. Variant forms of the ZIC2 protein, associated with HPE in man or mouse, are deficient in their ability to influence SMAD-dependent transcription. These findings reveal a new mechanism of NODAL signal transduction in the mammalian node and provide the first molecular explanation of how ZIC2 loss-of-function precipitates HPE.
cell therapies
2025-06-19 | Surgical Nuances in Ultrasound-Guided Percutaneous Distal Catheter Placement in Pediatric Ventriculoatrial Shunts.
Currently, there is no universally accepted consensus regarding the optimal site for distal catheter placement in patients with congenital hydrocephalus and a non-functional peritoneal cavity, as therapeutic strategies must be meticulously individualized based on each patient's unique anatomical and physiological considerations. We report a complex case involving a one-year-old male infant, born prematurely, with alobar holoprosencephaly (HPE) and congenital hydrocephalus, who experienced multiple ventriculoperitoneal shunt (VPS) failures. These complications were attributed to impaired peritoneal absorption of cerebrospinal fluid (CSF), recurrent shunt infections, and occlusion of an external ventricular drainage system. As a salvage intervention, a ventriculoatrial shunt (VAS) was successfully established using ultrasound-guided internal jugular vein cannulation, followed by fluoroscopy-assisted endovascular placement of a modified distal catheter via the Seldinger technique. This approach underscores the utility of image-guided VAS as a viable alternative in cases of VPS failure secondary to peritoneal CSF resorption insufficiency, particularly in patients with complex neuroanatomical profiles.
2023-09-08 | Alobar holoprosencephaly: A case report
Introduction: Holoprosencephaly (HPE) is a rare brain malformation, which results from a cleavage defect of the prosencephalon. Three forms have been described as: alobar, semi-lobar, and lobar forms. Case Report: We report a rare case of holoprosencephaly, diagnosed at the maternity of the Ibn Rochd Hospital Center in Casablanca. Conclusion: Holoprosencephaly is secondary to a cleavage anomaly of the prosencephalon, the diagnosis is based on echotomography, computed tomography (CT) scan and nuclear magnetic resonance imaging (MRI). It is important to perform a karyotype to look for a chromosomal anomaly. Holoprosencephaly, although rare, should be recognized and diagnosed; minor forms are likely to benefit from medical replacement therapy or ventricular shunting.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.